Table 3.

Clinical characteristics of the 10 patients with non-AD primary neuropathological diagnosis

Primary neuropathological diagnosis	Age at symptom onset	Age at death	Diagnosis	sex	APOE4 status	Thal phase	NFT Braak stage	CERAD score	ADNC level	Site
LBD	67	71	PCA plus	M	e4 carrier	5	IV	moderate	intermediate	S01
LBD	61	70	PCA pure	F	-	-	IV	frequent	intermediate	S03
LBD	58	68	-	M	e4 carrier	5	VI	frequent	high	S05
LBD	79	87	-	M	non-carrier	4	V	frequent	high	S05
FTLD-tau (CBD)	58	64	PCA plus	M	e4 carrier	2	II	sparse	low	S20
FTLD-tau (CBD)	51	57	PCA pure	M	non-carrier	0	0	none	none	S24
Brain infarct	90	91	-	F	-	1	0	sparse	low	S26
Brain infarct	88	94	-	F	-	0	0	none	none	S26
FTLD-TDP43 Type A	59	68	PCA pure	M	-	0	0	none	none	S24
FTLD-tau (Pick’s)	58	68	PCA pure	F	e4 carrier	2	I	moderate	low	S05

Abbreviations: LBD: Lewy body disease, FTLD: frontotemporal lobar degeneration, CBD: corticobasal degeneration, TDP-43: TAR DNA-binding protein 43, APOE4: allele ε4 of the apolipoprotein E gene, NFT: Neurofibrillary Tangles, CERAD: Consortium to Establish a Registry for Alzheimer’s Disease, ADNC: Alzheimer’s Disease Neuropathological changes, MMSE: Mini-Mental State Examination; CDR: Clinical Dementia Rating scale. Corresponding site descriptions can be found in Supplementary Table 2.